grant
Alloimmune-compatible stem cells for ocular diseases
Organization SCHEPENS EYE RESEARCH INSTITUTELocation BOSTON, UNITED STATESPosted 1 Jan 2025Deadline 31 Dec 2029
NIHUS FederalResearch GrantFY2025ABC Transporter, MHC, 2ABC17ABCB2ABCB3APT2ATP-Binding Cassette, Sub-Family B, Member 3AddressAffectAffinityAllogenicAntigen Peptide Transporter 2AssayAutologousB blood cellsB cellB cellsB-CellsB-LymphocytesB-cellBindingBioassayBiochemicalBiological AssayBody TissuesCD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCRISPR approachCRISPR based approachCRISPR methodCRISPR methodologyCRISPR techniqueCRISPR technologyCRISPR toolsCRISPR-CAS-9CRISPR-based methodCRISPR-based techniqueCRISPR-based technologyCRISPR-based toolCRISPR/CAS approachCRISPR/Cas methodCRISPR/Cas technologyCRISPR/Cas9CRISPR/Cas9 technologyCas nuclease technologyCell BodyCell LineCell ProtectionCell TherapyCell TransplantationCell-Mediated CytolysisCell-Mediated LympholysisCellLineCellsCellular CytotoxicityCessation of lifeClass I AntigensClass I Major Histocompatibility AntigensClustered Regularly Interspaced Short Palindromic Repeats approachClustered Regularly Interspaced Short Palindromic Repeats methodClustered Regularly Interspaced Short Palindromic Repeats methodologyClustered Regularly Interspaced Short Palindromic Repeats techniqueClustered Regularly Interspaced Short Palindromic Repeats technologyComplexComplex Class 1ConsumptionCorneaCytolysisCytoprotectionCytotoxic cellD6S114EDataDeathDevelopmentERp57EndodermEndoderm CellEndodermal CellEngineeringEnsureEnzyme GeneEnzymesEyeEye diseasesEyeballFlow CytofluorometriesFlow CytofluorometryFlow CytometryFlow MicrofluorimetryFlow MicrofluorometryGene DeletionGene InactivationGene SilencingGenerationsGenesHL-A AntigensHLA AntigensHistocompatibility Antigens Class IHumanHuman Leukocyte AntigensImmuneImmune responseImmune systemImmunesImmunityImmunocompetentImmunosuppressionImmunosuppression EffectImmunosuppressive EffectIn VitroK lymphocyteKnock-outKnockoutLeukocyte AntigensLymphocyte CytotoxicityLymphocytotoxicityLysisLytotoxicityMHC Class I MoleculeMHC Class I ProteinMHC class I antigenMajor Histocompatibility Complex Class 1MediatingMiceMice MammalsModern ManMolecular InteractionMorbidityMorbidity - disease rateMurineMusNK CellsNK T cellNKT cellNatural Killer CellsNatural Killer T cellNatural regenerationPSF1PSF2PatientsPeptide Supply Factor 2Peptide Transporter PSF2PeptidesPilot ProjectsProcessProductionProgenitor CellsRING11RING4RegenerationRegenerative MedicineResearch ResourcesResourcesRiskSourceStandardizationStem Cell likeStrains Cell LinesSurfaceSystemT-Cell ActivationT8 CellsT8 LymphocytesTAP-A proteinTAP1TAP1 geneTAP2TAP2 geneTechniquesTestingTimeTissuesTransgenesTransplantationTransporter, ATP-Binding Cassette, Major Histocompatibility Complex, 2Validationactivate T cellsalloimmunityallotransplantallotransplantationcell bankcell based interventioncell mediated cytotoxicitycell mediated interventioncell mediated therapiescell transformationcell typecell-based therapeuticcell-based therapycellular therapeuticcellular therapycellular transplantclinical applicabilityclinical applicationcornealcostcultured cell linecytoprotectivecytotoxiccytotoxic CD8 T cellscytotoxic CD8 T lymphocytecytotoxicitydevelopmentalepithelial progenitorepithelial progenitor cellepithelial stem celleye disorderflow cytophotometrygene deletion mutationgene editing platformgene editing systemgene editing technologygene editing toolsgene-editing toolkithiPSChost responsehuman iPShuman iPSChuman induced pluripotent cellhuman induced pluripotent stem cellshuman inducible pluripotent stem cellshuman inducible stem cellshumanized micehumanized mouseiPSiPSCiPSCsimmune competentimmune suppressionimmune suppressive activityimmune suppressive functionimmune system responseimmunogenicimmunogenicityimmunoresponseimmunosuppressive activityimmunosuppressive functionimmunosuppressive responsein vivoinduced human pluripotent stem cellsinduced pluripotent cellinduced pluripotent stem cellinducible pluripotent cellinducible pluripotent stem cellinnovateinnovationinnovativeisoimmunityknockout genelimbalmembermouse modelmurine modelnatural killer T lymphocytenovelocular diseaseocular disorderophthalmopathyoverexpressoverexpressionpilot studypluripotencypluripotent statepreservationprogenitor capacityprogenitor cell based therapyprogenitor cell likeprogenitor cell therapyprogenitor cell treatmentprogenitor therapyprogenitor treatmentprogenitor-likeregenerateregenerate new tissueregenerate tissueregenerating damaged tissueregenerating tissueregenerativeresponsestem and progenitor cell therapystem cell based therapystem cell characteristicsstem cell mediated therapystem cell therapeuticsstem cell therapystem cell treatmentstem cell-based therapeuticstem cell-based treatmentstem cellsstem-likestemnesssuccesstapasintechnological innovationtissue regenerationtissue regrowthtissue renewaltissue specific regenerationtooltranscriptional silencingtransformed cellstransgenetransplantvalidations
Description preview
SUMMARY: Induced pluripotent stem cells (iPSCs) possess remarkable ability to transform into various cell
types found in the eye, making them an exceptional cellular resource for regenerating ocular tissues. However,
while the use of autologous iPSCs ensures immune compatibility, it still has no clinical applicability to date, given
the time and…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click